StatPearls-/-ä 2024[Jan]; ä (ä): ä PMID34283490show ga
As of January 24, 2022, according to the United States Food and Drug Association (FDA) fact-sheet for casirivimab, "due to the high frequency of the Omicron variant, casirivimab is not currently authorized for use in any U.S. region because of markedly reduced activity against the omicron variant. This drug may not be administered for treatment or post-exposure prevention of COVID-19 under the Emergency Use Authorization until further notice by the Agency." This article is to be used only for a historical review of the development and use of this drug.